About: High plasma concentrations of beta-receptor blocking drugs and deficient debrisoquine hydroxylation

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: High plasma concentrations of beta-receptor blocking drugs and deficient debrisoquine hydroxylation Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 February 1982

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в лютому 1982 (uk) im Februar 1982 veröffentlichter wissenschaftlicher Artikel (de) scientific article published on 01 February 1982 (en) artículu científicu espublizáu en febreru de 1982 (ast)
publication date	wds:Q72520072-F7D7672B-3D5F-4DFB-8375-4EDFC3B00734
publication date	1982-02-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q72520072-2B05F9C0-E026-413F-8E61-DB94AA3D0FEC
language of work or name	English
cites work	wds:Q72520072-1D96EE03-01BF-478D-A7D3-DC45C526EA64 wds:Q72520072-472E1F5B-B6CC-4562-AB02-166AADEC2BDA wds:Q72520072-5FAB5FDD-7322-4506-91C0-24CBC1B66498 wds:Q72520072-8962B8D6-D569-4EB6-A148-30F269E757AD wds:Q72520072-94A06FB6-2636-499F-AD54-5AFB96F6CC43 wds:Q72520072-9AD81C44-3661-454D-972E-AFD6D9F5F6FF wds:Q72520072-A6012709-EAD9-438B-BC92-86F642C8C18E wds:Q72520072-A6652679-E607-4D15-8F5F-0884DD0E6FA3 wds:Q72520072-D200FA79-7F7E-447C-BB59-5E5B8C7099B9 wds:Q72520072-F9DE18F3-55A7-470A-87FE-EAF67C3AD42C
cites work	Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction Polymorphic hydroxylation of Debrisoquine in man. A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. Pharmacokinetic and pharmacodynamic properties of metoprolol in patients with impaired renal function Prazosin first dose phenomenon during combined treatment with a beta-adrenoceptor blocker in hypertensive patients Evidence for an enzymatic defect in the 4-hydroxylation of debrisoquine by human liver Metabolism of metoprolol-(3-h) in man, the dog and the rat Value of anion-gap determination in multiple myeloma Anion Gap in Multiple Myeloma The Possible Role of Cytochrome P-450 in the Liver “First Pass Elimination” of a P-Receptor Blocking Drug
author name string	wds:Q72520072-97B3C1D7-A209-45F6-874C-61932F9C64D3 wds:Q72520072-A2F3F1E1-7248-4EC8-9400-14D05A6D678E wds:Q72520072-B369A68F-F1F4-4DE2-8B85-2B4DB019F56B wds:Q72520072-CEEF69C5-8588-4A7F-B4BF-85E0017E6681
author name string	F Sjöqvist C von Bahr G Alvan P Seidemann
rdfs:label	High plasma concentrations of beta-receptor blocking drugs and deficient debrisoquine hydroxylation (en) High plasma concentrations of beta-receptor blocking drugs and deficient debrisoquine hydroxylation (nl) High plasma concentrations of beta-receptor blocking drugs and deficient debrisoquine hydroxylation (sq)
skos:prefLabel	High plasma concentrations of beta-receptor blocking drugs and deficient debrisoquine hydroxylation (en) High plasma concentrations of beta-receptor blocking drugs and deficient debrisoquine hydroxylation (nl) High plasma concentrations of beta-receptor blocking drugs and deficient debrisoquine hydroxylation (sq)
name	High plasma concentrations of beta-receptor blocking drugs and deficient debrisoquine hydroxylation (en) High plasma concentrations of beta-receptor blocking drugs and deficient debrisoquine hydroxylation (nl) High plasma concentrations of beta-receptor blocking drugs and deficient debrisoquine hydroxylation (sq)
title	wds:Q72520072-F594447A-EA83-4001-BE65-7441A6AD418D
title	High plasma concentrations of beta-receptor blocking drugs and deficient debrisoquine hydroxylation (en)
page(s)	wds:Q72520072-EA91249C-88FE-4BF8-B03D-F2CC44FE4EC5
page(s)	333
instance of	wds:Q72520072-DC6A23FF-BB06-43FF-B03F-4C808A675F42
instance of	scholarly article
PubMed ID	wds:Q72520072-3FADD917-D9C1-4FD6-B659-F4118A6595D7
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/6120324
PubMed ID	6120324
published in	wds:Q72520072-2896AE7A-779D-411D-BD81-543D2C274AE1
published in	The Lancet
issue	wds:Q72520072-CBA3F90F-5AF3-496E-8885-80E97C9D6290
volume	wds:Q72520072-BA8FE4EE-E048-4FD5-8A8E-F0F68243FC39
issue	8267
volume	1
DOI	wds:Q72520072-44C364F0-A1D4-4998-A2AE-78A8739F7A71
DOI	http://dx.doi.org/10.1016/S0140-6736(82)91583-5
DOI	10.1016/S0140-6736(82)91583-5
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q72520072
is cites work of	Recent developments in hepatic drug oxidation. Implications for clinical pharmacokinetics Assessment of the drug metabolism capacity of the liver Ethnic differences in drug disposition and responsiveness Competitive inhibition of sparteine oxidation in human liver by β-adrenoceptor antagonists and other cardiovascular drugs Assessment of Methods to Identify Sources of Interindividual Pharmacokinetic Variations Oxprenolol absorption in man after single bolus dosing into two segments of the colon compared with that after oral dosing Plasma levels of (+) and (-)-propranolol and 4-hydroxypropranolol after administration of racemic (+/-)-propranolol in man Genetically determined variability in acetylation and oxidation. Therapeutic implications Drug-related lupus. Incidence, mechanisms and clinical implications Timolol and atenolol: relationships between oxidation phenotype, pharmacokinetics and pharmacodynamics Defective metabolism of metoprolol in poor hydroxylators of debrisoquine Encainide and its metabolites. Comparative effects in man on ventricular arrhythmia and electrocardiographic intervals Should every survivor of a heart attack be given a beta-blocker? Part III. Some conclusions Should every survivor of a heart attack be given a beta blocker? Part II. Evidence from a clinical pharmacological standpoint The effect of hydralazine on steady-state plasma concentrations of metoprolol in pregnant hypertensive women Pharmacogenetic perspectives: genes, drugs and disease Protecting poor metabolizers, a group at high risk of adverse drug reactions Comparison of two long-acting preparations of metoprolol with conventional metoprolol and atenolol in healthy men during chronic dosing The polymorphic oxidation of beta-adrenoceptor antagonists. Clinical pharmacokinetic considerations Influence of debrisoquine oxidation phenotype on exercise tolerance and subjective fatigue after metoprolol and atenolol in healthy subjects Oxidation phenotype and the metabolism and action of beta-blockers Contribution of the genetic status of oxidative metabolism to variability in the plasma concentrations of beta-adrenoceptor blocking agents Bufuralol metabolism in human liver: a sensitive probe for the debrisoquine-type polymorphism of drug oxidation Genetically determined polymorphisms in drug oxidation Metabolic basis of adverse drug reactions Beta adrenoceptor antagonists after myocardial infarction--where are we now? A simple borohydride/GC method for measuring sparteine metabolites in man Interactions of bupranolol with the polymorphic debrisoquine/sparteine monooxygenase (CYP2D6) Desipramine pharmacokinetics in Chinese and Caucasian volunteers Inhibitory effects of neuroleptics on debrisoquine oxidation in man Role of oxidation polymorphism on blood and urine concentrations of amitriptyline and its metabolites in man Polymorphic metabolism of the beta-adrenoreceptor blocking drugs and its clinical relevance Polymorphic metabolism of beta-adrenoceptor antagonists Prevalence of debrisoquine oxidation phenotypes in glaucoma patients.

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 172 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software